Skip to Content

About Us

Strategic Alliances

In some instances our relationships with specific companies evolve into a long term and strategic commitment.  When mutually beneficial, formal Strategic Alliances are formed.  Each relationship is unique, but generally the alliances include a joint steering committee that meets regularly, dedicated project managers on both sides, master clinical and preclinical agreements, and a financial commitment. 

MedImmune

MD Anderson, MedImmune join forces on immunotherapy. 

view press release (March 14, 2014)

 

Johnson & Johnson Innovation / Janssen Biotech, Inc.

MD Anderson will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech Inc., to develop immunology-based cancer treatments through our Moon Shots Program's immunotherapy platform.

  

View press release (January 21, 2014)

 

Pfizer 

MD Anderson and Pfizer will collaborate in the development of immune-based approaches to cancer treatment, the first such agreement made through MD Anderson's Moon Shots Program immunotherapy platform. 

View press release (January 6, 2014)

 

Bayer Healthcare

Bayer HealthCare Announces Collaboration with MD Anderson. Clinical programs and collaborations in oncology to be jointly performed over three years. 

View press release (December 11, 2013) 

 

Boston Strategics 

Boston Strategics Announces Strategic Alliance with MD Anderson for Oncology Drug Development. 

View press release (July 25, 2013)

 

GlaxoSmithKline 

GlaxoSMithKline, MD Anderson Formalize Collaboration in Cancer Research. 

View press release (November 5, 2007)

 

Onyx Pharmaceuticals

Onyx Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance in Multiple Myeloma and Lymphoma. 

View press release (June 4, 2012)


© 2014 The University of Texas MD Anderson Cancer Center